Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $116,022.20 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 980 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $118.39, for a total value of $116,022.20. Following the completion of the sale, the chief executive officer now directly owns 137,658 shares of the company’s stock, valued at approximately $16,297,330.62. This represents a 0.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Kyle Gano also recently made the following trade(s):

• On Friday, January 31st, Kyle Gano sold 1,541 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.87, for a total value of $235,572.67.
• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00.

Neurocrine Biosciences Stock Up 0.3 %

Shares of NASDAQ NBIX traded up $0.33 on Wednesday, hitting $117.18. The company had a trading volume of 2,148,807 shares, compared to its average volume of 1,350,825. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The firm has a market capitalization of $11.86 billion, a P/E ratio of 35.62 and a beta of 0.33. The business has a 50 day moving average of $138.49 and a two-hundred day moving average of $131.02.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Vanguard Group Inc. lifted its stake in shares of Neurocrine Biosciences by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company’s stock valued at $1,381,331,000 after purchasing an additional 122,681 shares during the last quarter. State Street Corp increased its holdings in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after buying an additional 539,936 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company’s stock valued at $255,523,000 after buying an additional 15,830 shares in the last quarter. Wellington Management Group LLP raised its position in Neurocrine Biosciences by 102.9% in the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock worth $198,939,000 after purchasing an additional 739,199 shares during the last quarter. Finally, Braidwell LP lifted its position in Neurocrine Biosciences by 20.9% during the 3rd quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after purchasing an additional 158,665 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Neurocrine Biosciences in a report on Tuesday. They set a “hold” rating and a $138.00 target price on the stock. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Piper Sandler reiterated an “overweight” rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. UBS Group boosted their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. Finally, StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Monday. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.